2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2946

Large Scale Genetic Analysis in BehçEt Disease. Identification of Residues Associated in the HLA Class I Region and New Susceptibility Loci
Abstract Number: 1698

Late Onset Psoriatic Arthritis in a Longitudinal Cohort: Disease Presentation, Activity over Time and Prognosis
Abstract Number: 2965

Late-Onset Relapse in Patients with Systemic Vasculitis
Abstract Number: 40

Lateral Epicondylitis Treatment: Comparison of Bandage, Laser Therapy and Extra-Corporeal Shock Wave Therapy
Abstract Number: 734

Lateral Spine BMD Measurement and Trabecular Bone Score Can Represent a Bone Loss in Patients with Advanced Ankylosing Spondylitis
Abstract Number: 3063

Learning Rheumatology through Fellow-Generated Questions: The Rheumatology Image of the Week Project
Abstract Number: 244

Leflunomide and Glucocorticoids Combination Therapy for the Induction and Maintenance of Remission in Patients with IgG4-Related Disease
Abstract Number: 1618

Leflunomide, Sulfasalazine and Hydroxychloroquine for Rheumatoid Arthritis: Efficacious but Poorly Tolerated
Abstract Number: 317

Leg Muscle Imbalance Is Associated with Radiographic Grade or Pain in Knee Osteoarthritis
Abstract Number: 1113

Leptin Promotes Distribution of Mast Cells in Salivary Glands of Patients with Primary Sjogren’s Syndrome
Abstract Number: 2182

Levels of Severity of Hip and Knee OA – Validation of Lay Descriptions
Abstract Number: 112

Leveraging a Learning Network to Implement and Standardize Self-Management Support into Care Delivery: Experience of Pediatric Rheumatology Care and Outcomes Improvement Network
Abstract Number: 487

Limited Utility of Cytokine Profiles in Rheumatoid Arthritis Patients with Clinically Active Disease and Normal Inflammatory Indices
Abstract Number: 380

Linear Discriminant Analysis of Cultured Fibroblast-like Synoviocytes Identifies 6 Candidate Genes Which Predict Extended Course in Juvenile Idiopathic Arthritis
Abstract Number: 3023

Lipid Profile and Effect of Statin Treatment in Pooled Phase 2 and Phase 3 Baricitinib Studies

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].